Welcome to our dedicated page for AMDOCS SEC filings (Ticker: DOX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Amdocs Limited SEC filings document the disclosures of a foreign private issuer that provides software and services to communications and media companies. Its Form 6-K reports include quarterly and annual financial materials, consolidated financial statements, operating and financial review, earnings presentations, and disclosures on equity activity and issuer purchases.
The filing record also covers shareholder meeting materials and voting results, including board elections, employee share purchase plan amendments, dividend program approvals, auditor ratification, and governance changes involving executive leadership and board composition. Registration-statement incorporation language connects selected Form 6-K reports to Amdocs' equity compensation filings on Form S-8.
Amdocs Limited has a notice of proposed sale under Rule 144 covering 107,577 ordinary shares, to be sold through Oppenheimer & Co. Inc. on Nasdaq, with an aggregate market value of $5,510,093.94. The filing states that these shares were originally issued upon vesting of restricted stock units (RSUs) on several dates between November 15, 2020 and November 5, 2024, in amounts ranging from 12,189 to 31,732 shares, for which no cash consideration was paid on vesting.
Pzena Investment Management, LLC has filed Amendment No. 2 to a Schedule 13G reporting beneficial ownership of 14,200,759 shares of Amdocs Ltd common stock, representing 13.2% of the class. Pzena, a Delaware limited liability company, is acting as investment manager for underlying clients.
The firm reports sole voting power over 10,893,470 shares and sole dispositive power over all 14,200,759 shares, with no shared voting or dispositive power. Clients of Pzena have the right to receive dividends and sale proceeds from these securities, and no single client’s interest relates to more than five percent of the class.
A Form 144 notice was filed reporting a proposed sale of 50,853 shares of ordinary stock by a selling person associated with Amdocs Ltd. The filing also lists recent issuances upon RSU vesting of 39,963, 35,368 and 39,786 ordinary shares. The filing shows 108,448,276 shares outstanding as of 06/22/2026.
Amdocs Ltd Chief Financial Officer Tal Rozenfeld has filed an initial ownership report showing holdings of 22,743 Ordinary Shares as of June 1, 2026. The reported amount includes Ordinary Shares that are subject to outstanding restricted stock awards, reflecting both vested and unvested equity-based compensation.
Amdocs Ltd executive Matthew E. Smith reported an open-market sale of company stock. On this Form 4, he sold 464 Ordinary Shares of Amdocs on May 29, 2026 at an average price of $62.51 per share, for roughly $29,000 in proceeds.
After the transaction, Smith directly holds 1,550 Ordinary Shares of Amdocs. The filing reflects a routine insider sale rather than a change in compensation or option exercise, and no derivative securities are reported as remaining positions.
Morgan Stanley Smith Barney LLC submitted a Form 144 notice to sell 50,000 shares of common stock of the issuer on 06/01/2026. The filing states the sale follows an exercise of options under a registered plan and lists proceeds of $3,257,700.00.
DOX reported a proposed resale of 464 shares of Common Stock tied to restricted stock vesting under a registered plan on 05/29/2026.
The notice states the shares are being sold by the issuer in connection with services rendered and reflect vested restricted stock; cash‑flow treatment and buyer details are not included in the excerpt.
Amdocs Limited reported modest revenue growth but lower profit for the six months ended March 31, 2026. Revenue rose 4.0% to $2,327.9M, helped by activity across all regions and recent acquisitions, including Matrixx Software.
Net income attributable to Amdocs fell to $295.4M from $314.4M, and diluted EPS edged down to $2.74 from $2.78, reflecting higher restructuring charges of $21.7M, increased amortization of intangibles and higher income taxes. Operating margin slipped to 16.7% from 17.7%.
Cash from operations strengthened to $321.8M, funding $217.7M of acquisitions, $284.5M of share repurchases and $113.8M of dividends, reducing cash to $214.5M. Twelve-month backlog reached $4.28B, up 2.6%. Amdocs also expanded its revolving credit facility to $800M and set up an $800M commercial paper program.
Amdocs Ltd notice: a Form 144 was filed reporting proposed sales of ordinary shares by an affiliate. The filing lists Restricted Stock Units from 11/15/2019 (46,811 shares) and 11/11/2020 (110,075 shares) and shows recent dispositions of 149,701 and 17,013 shares on 03/18/2026 and 03/19/2026 respectively, with proceeds recorded as 9,752,271.64 and 1,100,838.07.
Hortig Shimie reported acquisition or exercise transactions in this Form 4 filing.
Amdocs Ltd director and officer Shimie Hortig received an equity grant as part of his compensation. On May 13, 2026, he was awarded 84,483 Amdocs ordinary shares at no purchase price, described as time-based restricted stock awards that vest over three years from the grant date.
After this grant, Hortig directly holds 181,696 ordinary shares. Because this is a share award rather than an open-market trade, it reflects routine equity compensation rather than a discretionary stock purchase or sale.